Aurora Cannabis Reports Record Annual Medical Revenue & EBITDA, but Forecasts FY27 Revenue Decline and Lower EBITDA

summarizeSummary

Aurora Cannabis announced record annual medical cannabis revenue and adjusted EBITDA for FY26, but its Q4 results were mixed, and the company issued a negative outlook for FY27, forecasting declining revenue and lower EBITDA.

check_boxKey Events

• Record Annual Performance

  Achieved record annual global medical cannabis net revenue of $288.6 million (18% YoY growth) and record annual Adjusted EBITDA of $53.8 million (32% YoY growth) for fiscal year 2026.

• Mixed Q4 Financials

  Reported Q4 total net revenue of $84.8 million (10% YoY increase) driven by medical cannabis, but Adjusted EBITDA declined to $9.2 million from $14.1 million YoY, and free cash flow was $0.3 million, down from $5.2 million YoY.

• Negative FY27 Outlook

  Forecasts a decline in total net revenue for fiscal year 2027, aligning with FY25 levels, and expects lower annual Adjusted EBITDA compared to the prior fiscal year due to changes in Canadian medical pricing.

• Strong Cash Position

  Maintains a strong balance sheet with approximately $164.7 million in cash, short-term investments, and cash equivalents, with no debt.

auto_awesomeAnalysis

Aurora Cannabis reported record annual global medical cannabis net revenue and adjusted EBITDA for fiscal year 2026, demonstrating strong performance in its core medical segment. However, the fourth quarter saw a decline in adjusted EBITDA and free cash flow, and more critically, the company provided a negative outlook for fiscal year 2027, projecting a decline in total net revenue and lower annual adjusted EBITDA. This forward guidance suggests a challenging year ahead despite past successes, which is a significant market-moving signal.